A novel dual inhibitor of HER1 and HER2 protein tyrosine kinases

被引：0
|
作者：
Mastalerz, H
Dextraze, P
Gavai, A
Johnson, W
Lee, F
Oppenheimer, S
Ruediger, E
Tarrant, J
Vite, G
Vyas, D
Wong, TW
Zhang, GF
Zhang, HJ
机构：
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Discovery Chem, Wallingford, CT 06492 USA
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Oncol Drug Discovery, Wallingford, CT 06492 USA
[3] Bristol Myers Squibb Co, Pharmaceut Res Inst, PCO, Wallingford, CT 06492 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2005年 / 230卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
379-MEDI
引用
收藏
页码：U2717 / U2717
页数：1
相关论文
共 50 条
  • [1] BMS-599626: A novel dual inhibitor of HER1 and HER2 protein tyrosine kinases.
    Gavai, AV
    Fink, BE
    Tokarski, JS
    Fairfax, D
    Martin, G
    Grubb, L
    Fu, Z
    Kim, SH
    Leavitt, K
    Mastalerz, H
    Mitt, T
    Hunt, JT
    Kadow, JF
    Du, KR
    Han, WC
    Norris, D
    Goyal, B
    Vyas, DM
    Yu, C
    Oppenheimer, S
    Zhang, HJ
    Lee, FY
    Wong, TW
    Vite, GD
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U108 - U108
  • [2] New dual inhibitors of HER1 and HER2 protein tyrosine kinases.
    Vite, GD
    Mastalerz, H
    Fink, BE
    Gavai, AV
    Hunt, JT
    Tokarski, JS
    Vyas, DM
    Wong, TW
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U3 - U3
  • [3] Preclinical adme evaluation of BMS-599626, a dual inhibitor of HER1 and HER2 receptor tyrosine kinases
    Zhang, Hongjian
    Yao, Ming
    Sleczka, Bogdan
    Davis, Carl
    Ryan, Patricia
    Iyer, Rama
    Marathe, Punit
    [J]. DRUG METABOLISM REVIEWS, 2006, 38 : 161 - 162
  • [4] Exploration of an aminothiazole dual HER2/HER1 kinase inhibitor.
    Mastalerz, H
    Chang, M
    Johnson, W
    Kadow, J
    Langley, D
    Vite, G
    Vyas, D
    Wong, TW
    Zhang, GF
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U12 - U12
  • [5] New dual inhibitors of EGFR and HER2 protein tyrosine kinases
    Fink, BE
    Vite, GD
    Mastalerz, H
    Kadow, JF
    Kim, SH
    Leavitt, KJ
    Du, K
    Crews, D
    Wong, TW
    Hunt, JT
    Vyas, DM
    Tokarski, JS
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) : 4774 - 4779
  • [6] Lapatinib, a Dual HER1/HER2 Tyrosine Kinase Inhibitor, Augments Basal Cleavage of HER2 Extracellular Domain (ECD) to Inhibit HER2-Driven Cancer Cell Growth
    Vazquez-Martin, Alejandro
    Oliveras-Ferraros, Cristina
    Cufi, Silvia
    del Barco, Sonia
    Martin-Castillo, Begona
    Menendez, Javier A.
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (01) : 52 - 57
  • [7] Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
    Cristina Oliveras-Ferraros
    Sílvia Cufí
    Tamara Sauri-Nadal
    Sonia Del Barco
    Begoña Martin-Castillo
    Alejandro Vazquez-Martin
    Javier A Menendez
    [J]. Breast Cancer Research, 13
  • [8] Cytogenetic analysis of Her1/EGFR, Her2/neu, Her3, and hEr4 receptor tyrosine kinases in breast cancer
    Sassen, A.
    Rochon, J.
    Wild, P.
    Hartmann, A.
    Hofstaedter, F.
    Schwarz, S.
    Brockhoff, G.
    [J]. CYTOMETRY PART A, 2007, 71A (07) : 515 - 515
  • [9] Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
    Oliveras-Ferraros, Cristina
    Cuff, Silvia
    Sauri-Nadal, Tamara
    Del Barco, Sonia
    Martin-Castillo, Begona
    Vazquez-Martin, Alejandro
    Menendez, Javier A.
    [J]. BREAST CANCER RESEARCH, 2011, 13 (01):
  • [10] TRANSMODULATION OF HER2 LEVELS BY HER1 ACTIVATION
    WORTHYLAKE, B
    WILEY, HS
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1995, 6 : 1374 - 1374
12345